Sponsors
The bill directs modest, multi-year federal funding and coordinated VA–DoD research to accelerate diagnostics and treatments for veterans exposed to repetitive low-level blasts and increases oversight, but it imposes modest taxpayer cost, administrative burdens, potential research crowding, and data-privacy risks for service members and veterans.
Veterans with repetitive low-level blast exposure and dementia will receive targeted research and faster identification of diagnostics and treatments through expanded initiative coverage and VA–DoD data sharing and big‑data studies.
Veterans and the public will gain regular independent oversight and clearer biomarker standards via biennial reporting and National Academies validation, improving transparency and scientific rigor.
Veterans and participating hospitals/health systems will benefit from a stable $5 million per year authorization (FY2025–2030) to carry out the initiative's research and implementation activities.
Service members and veterans face increased privacy and data‑security risks from expanded VA–DoD data sharing unless robust safeguards are implemented.
Taxpayers will bear an estimated $30 million federal authorization over six years, a modest fiscal cost that could displace other priorities.
Veterans and patients with chronic conditions may see resources concentrated on specified interventions (e.g., growth hormone replacement), potentially crowding out other promising lines of inquiry.
Based on analysis of 2 sections of legislative text.
Expands VA precision-medicine research to include repetitive low-level blast exposure and dementia, mandates VA–DoD data sharing and biomarker validation, and authorizes $5M/yr for FY2025–FY2030.
Introduced March 26, 2026 by Mariannette Miller-Meeks · Last progress March 26, 2026
Expands a VA precision-medicine research initiative to add repetitive low-level blast exposure and dementia to the list of covered conditions, requires a VA–DoD data‑sharing partnership, mandates targeted research and oversight (including biomarker validation via a National Academies contract), and sets reporting and assessment requirements. It also authorizes $5,000,000 per year for FY2025–FY2030 to carry out the initiative, and establishes short deadlines for key steps (60 days to seek the National Academies contract; 1 year to form the VA–DoD data partnership).